| 價格 | ¥300 |
| 包裝 | 100μg |
| 最小起訂量 | 1支 |
| 發(fā)貨地 | 湖北 |
| 更新日期 | 2026-06-08 |
| 英文名稱:Ensituximab | CAS:1092658-06-4 |
| 品牌: Mabnus | 產(chǎn)地: 武漢 |
| 保存條件: store at -20°C or -80°C. Avoid repeated freeze. | 純度規(guī)格: >98% by SDS-PAGE |
| 重組: 是 | 應(yīng)用: ELISA;FC;Functional Assays;IF |
| 種屬反應(yīng)性: Human | 宿主: Chimeric |
| 偶聯(lián)物: 否 | 靶點: MUC5AC |
| 免疫原: MUC5AC | 亞型: IgG1 - kappa |
| 驗證方法: (Ensituximab)Biosimilar Reference Antibody(GS40232) on SDS-PAGE under non-reducing (NR) and reducing (R) condition. |
貨號:GS40232
Ensituximab (also known as NEO-102 and NPC-1C) is a novel, chimeric immunoglobulin G1 (IgG1) monoclonal antibody developed as a biological therapy for patients with pancreatic and colorectal cancers. It was designed to bind to a set of human colorectal and pancreatic carcinoma-associated antigens. The exact molecular target(s) of ensituximab remain(s) uncertain, representing a unique and challenging aspect of its development. While initially described as targeting undefined tumor-associated antigens, subsequent research suggested that its primary target might be the specific mucin protein MUC5AC. The intended mechanism of action involves binding to these antigens on the surface of cancer cells, potentially inhibiting tumor-promoting functions and marking the cells for immune-mediated destruction (e.g., via ADCC).
| 成立日期 | 2021-07-13 (6年) | 注冊資本 | 壹佰伍拾萬圓人民幣 |
| 員工人數(shù) | 10-50人 | 年營業(yè)額 | ¥ 1000萬-5000萬 |
| 主營行業(yè) | 抗體,蛋白組學 | 經(jīng)營模式 | 工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| 詢價 |
碧云天生物技術(shù)有限公司
|
2026-07-28 | ||
| 詢價 |
VIP4年
|
上海賽可銳生物科技有限公司
|
2026-07-29 | |
| ¥2150.00 |
VIP11年
|
北京索萊寶科技有限公司
|
2026-07-30 | |
| 詢價 |
VIP5年
|
TargetMol中國(陶術(shù)生物)
|
2026-06-29 |